The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | The use of CLL-IPI, a new prognostic index for CLL
Jasmin Bahlo, PhD of University of Cologne, Cologne, Germany gives an overview CLL-IPI and its use in chronic lymphocytic leukemia (CLL) at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. The paper on CLL-IPI was published this year and Dr Bahlo explains that they are working on guidelines for CLL in Germany, in which they have integrated a recommendation on the use of the IPI. Dr Bahlo believes it will take some time for the tool to be adopted. They are generating data on its applicability but more data is needed to confirm its utility. She explains that they want this tool to be a basis like the Rai and the Binet system before, so that everyone uses it and all the results generated across different centers and institutions are comparable.
